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Abstract
It has long been recognized that cardiac autonomic neuropathy increases morbidity and mortality in diabetes and may have
greaterpredictive power than traditional riskfactors forcardiovascularevents.Signiﬁcant morbidity andmortality can now be
attributable to autonomic imbalance between the sympathetic and parasympathetic nervous system regulation of
cardiovascular function. New and emerging syndromes include orthostatic tachycardia, orthostatic bradycardia and an
inability to use heart rate as a guide to exercise intensity because of the resting tachycardia. Recent studies have shown that
autonomicimbalancemaybeapredictorofriskofsuddendeathwithintensiﬁcationofglycaemiccontrol.Thisreviewexamines
an association of autonomic dysregulation and the role of inﬂammatory cytokines and adipocytokines that promote
cardiovascularrisk.Inaddition,conditionsofautonomicimbalanceassociatedwithcardiovascularriskarediscussed.Potential
treatment for restoration of autonomic balance is outlined.
Diabet. Med. 28, 643–651 (2011)
Introduction
Physiologicalactivitiesofthecardiovascularsystemareunderthe
control of the autonomic nervous system. Analysis of heart rate
variability is a non-invasive electrocardiographic method for
assessing overall autonomic activity. Analysis of heart rate
variability, with analysis of respiratory activity, independently
and simultaneously measures parasympathetic and sympathetic
activity [1] and thereby provides information with regard to
autonomic balance of the cardiovascular system. Autonomic
balance involves complex interactions with several physiologic
mechanisms that act to maintain heart rate and blood pressure
within normal limits. Recent investigations have suggested that
autonomic dysfunction (e.g. heightened activity of the
sympathetic nervous system and suppressed activity of
the parasympathetic nervous system) impairs the ability of the
autonomicnervoussystemtoregulatethecardiovascularsystem.
New and emerging syndromes include orthostatic tachycardia,
orthostatic bradycardia and an inability to use heart rate as a
guide to exercise intensity because of the resting tachycardia.
With a growing understanding of bi-directional interactions
betweenthesympatheticandparasympatheticefferentpathways
at different levels of the neuraxis and at target organs [2], it is
possible that autonomic imbalance may be shown to be a key
componentinvolved in both theaetiology andthe clinicalcourse
of cardiovascular disease.
Morbidity and mortality
Cardiac autonomic neuropathy deﬁned by measures of
abnormalities of the parasympathetic and sympathetic nervous
systems is a signiﬁcant cause of morbidity and mortality
associated with a high risk of cardiac arrhythmias and sudden
death, possibly related to silent myocardial ischaemia.
Cardiovascular events are the main cause of excess mortality
among patients with both Type 1 and Type 2 diabetes [3]. The
prevalence of cardiac autonomic neuropathy varies greatly
depending on the criteria used to identify cardiac autonomic
neuropathy, the assessment modalities and the patient cohort
studied. These range from as low as 1.6 to 2.6% of the primary
prevention cohort in the Diabetes Control and Complications
Trial (DCCT) [4] to as high as 90% of patients with long-
standing Type 1 diabetes who were potential candidates for a
pancreastransplant[5].InalargecohortofpatientswithType 1
and Type 2 diabetes, Ziegler and colleagues, using predeﬁned
heart rate variability and spectral analysis of the R-R intervals,
found that 25.3% of patients with Type 1 diabetes and
34.3% of those with Type 2 diabetes had abnormal ﬁndings
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is associated with a decreased parasympathetic modulation of
the heart and a shift toward augmented sympathetic tone. Thus,
parasympathetic tone may decline with an autonomic
imbalance shifting toward augmented sympathetic tone during
the development from normal glucose tolerance to impaired
glucose tolerance and ﬁnally diabetes [7].
Reduced heart rate variability as a marker of autonomic
dysfunction has been shown to have dire consequences in terms
of morbidity (e.g. progression of coronary atherosclerosis) and
mortality [8], independent of cardiovascular risk factors in
various populations, including those with pre-diabetes and
diabetes [9] [10]. In Type 1 diabetes, there is a fourfold
increased risk of death [11]. Clearly the role of autonomic
imbalance and the mechanisms underlying the risk require
further exploration if we are to achieve beneﬁt for all.
Is hyperglycaemia and its control the solution to the impact
of autonomic imbalance on morbidity and mortality?
Thebeneﬁcialeffectofglycaemiccontrolonheartratevariability
shown in the Epidemiology of Diabetes Interventions and
Complications (EDIC) study [12] waned after several years
[13]. In Type 2 diabetes, the beneﬁt of multifactorial risk
intervention after 7.8 years could be retained after a further
observation period of 5.5 years, as shown in the Steno Trial [14]
[15]. In contrast, in the Veterans Affairs Diabetes Trial (VADT),
atrendtowardanincreaseinincidenceofautonomicneuropathy
was noted in patients on intensive diabetes therapy as compared
with those on standard therapy [16]. The concept that historical
glycaemic control is a major determinant of diabetes control,
known as metabolic memory or the ‘legacy effect’, has recently
been reported for autonomic neuropathy in the Epidemiology of
Diabetes Interventions and Complications study [12]. In the
Diabetes Control and Complications Trial, intensive glycaemic
control achieved a reduction of HbA1c of 1.7%, (5 mmol⁄mol),
that over 6.5 years was associated with a 54% reduction in the
incidence of cardiac autonomic neuropathy when compared
withconventionaltreatment.At13 years’follow-up,HbA1cwas
similar in the originally randomized groups, yet the intensively
treated group still enjoyed a 30% lower rate of cardiac
autonomic neuropathy. This suggests a metabolic memory for
the impact of hyperglycaemia [17]. It is thought that metabolic
memoryistheresultoflong-termmolecularchanges,suchasﬂux
through the polyol and hexosamine pathways and activation of
protein kinase C [18], as well as oxidative and nitrosative stress
[19]. This suggests that therapies might be directed at some of
these downstream events [20]. Epidemiologic data strongly
support the role of cardiovascular risk factors such as smoking,
blood pressure and hyperlipidaemia in the development of
cardiac autonomic neuropathy [21] [22], and clinical and basic
research emphasize the role of these disturbances in function
[23]. The ﬁnal common pathway may include endothelial
dysfunction, inﬂammation, cytokine overproduction and
growth factor deﬁciency [1].
Are inﬂammatory cytokines and adipocytokines associated
with autonomic imbalance?
Interleukin 6 is a multifunctional cytokine that plays a central
role in inﬂammatory responses. There is also evidence for the
expression and activity of interleukin 6 in the nervous system.
C-reactive protein is an acute-phase reactant produced in the
liver in response to interleukin 6. These inﬂammatory markers,
C-reactiveproteinandinterleukin 6,werefoundtobeassociated
with reduced heart rate variability in a study of 264 middle-age
maletwinsfreeofsymptomaticcoronaryarterydisease[24].The
results of this cross-sectional study suggest that autonomic
dysregulation may lead to inﬂammation providing a pathway
through which traditional risk factors promote the development
of cardiovascular disease. It has been hypothesized that
inﬂammation alters heart rate variability, but the opposite
directional relationship suggesting that autonomic changes
would be pro-inﬂammatory is also conceivable [24].
Experimental data support both possibilities. Both exposure to
acetylcholine and direct vagal stimulation inhibits release of
cytokines by macrophages [25]. Conversely, sympathetic
activation is pro-inﬂammatory. In isolated adipocytes,
b-stimulation increases interleukin 6 [26], whereas b-blockers
dampen the interleukin 6 increase normally seen in response to
stressinrats[27].Giventhatcause–effectrelationshipscannotbe
determined from cross-sectional studies, prospective studies will
beneededtodeterminewhetherautonomicdysfunctionmediates
the inﬂammatory process or if autonomic imbalance is a marker
ofinﬂammation.AnassociationbetweenbothC-reactiveprotein
and interleukin 6 and diabetic polyneuropathy has also recently
been demonstrated [28].
Hyperleptinaemia may be an important player in the
activation of the sympathetic nervous system in human obesity.
Leptin,aproductofthe obesity gene,issecreted fromadipocytes
and acts on the hypothalamus in the regulation of feeding and
energy balance. Intravenous infusion of leptin increases arterial
blood pressure and heart rate [29]. Adrenergic blockade
abolishes the effects of leptin, suggesting that the effects of
leptin were mediated by the sympathetic nervous system. In
humans,leptinlevelswereassociatedwithanincreaseinthelow-
frequency⁄high frequency-ratio (i.e. a shift of sympathovagal
balance toward increased sympathetic activation) independent
ofanthropomorphicmeasuresasshownin120non-obeseadults
[30].
Further support for a role of leptin in autonomic dysfunction
derives from the report by Murialdo et al. that bulimia nervosa
patients have altered heart rate variability associated with low
leptin levels and apparent sympathetic insufﬁciency [31]. The
weight-loss state is associated with profound effects on leptin
levels, as well as autonomic function which strive to alter
metabolic balance in favour of weight regain. With the
administration of leptin, energy expenditure, skeletal muscle
work efﬁciency and sympathetic tone, as well as levels of
thyroxine and triiodothyronine, are restored toward levels
prior to weight loss. Thus, the weight-reduced state may be
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leptin administration [32].
Leptin receptor-deﬁcient db⁄db mice develop Type 2
diabetes, hypertension and obesity, with a disrupted circadian
blood pressure. They also have higher resting heart rates and
greater heart rate responses to a-adrenergic agonists and
b-adrenergic blockers. However, blunted responses to atropine
and decreased baroreceptor responses, as well as loss of heart
rate variability, were also shown. Stimulation of central a-2
adrenoreceptors changed parasympathetic heart rate control
and baroreceptor sensitivity. Thus, the authors suggest that
db⁄db mice exhibit features found in humans with Type 2
diabetes and autonomic imbalance and could serve as a model
for further study. Whatever transpires, it cannot be denied that
there are important consequences of alterations in leptin
homeostasis with those of balance of the autonomic nervous
system [33].
Another adipocyte-derived protein that may be regulated by
the sympathetic nervous system is adiponectin. In a mouse
model, the sympathetic nervous system has been shown to
regulate adiponectin levels and its synthesis in white adipose
tissue in vivo [34]. In humans with autonomic imbalance (i.e.
predominant sympathetic activation), there were low levels of
circulating adiponectin [35] (i.e. a negative correlation between
adiponectin levels and the low-frequency⁄high-frequency
ratio). The low-frequency⁄high-frequency ratio was an
independent determinant of adiponectin levels (R
2 = 0.617).
Adiponectin depolarizes parvocellular paraventricular nucleus
neurons controlling neuroendocrine (ACTH not thyroid-
stimulating hormone) levels and acts in the hypothalamus
paraventricular nucleus to coordinate neuroendocrine and
autonomic function through its actions on speciﬁc functional
groups of paraventricular nucleus neurons [36]. In addition,
adiponectin acts in the nucleus of the solitary tract to reduce
blood pressure by modulating the excitability of neuropeptide
Y neurons [37], but may also lower blood pressure by direct
inhibition of the renal sympathetic nervous system [38].
Parasympathetic input to adipose tissue has been
demonstrated by Kreier et al. [39], illustrating that white
adipose tissue does receive dual autonomic control. This is
important in the regulation of cytokine release, as well as the
control of the release of free fatty acids and the development of
oxidative⁄nitrosative stress. Thus, it is possible, as suggested by
Kreier et al. [39], that an unbalanced autonomic nervous
system outﬂow to organs within the intra-abdominal
compartment (e.g. pancreas, liver, adipose tissue) may be a
factor in the development of diseases associated with intra-
abdominal obesity. There appears to be a closed-loop system,
wherein the adipose tissue mass regulates the hypothalamic
autonomic system, with both the sympathetic nervous system
and parasympathetic nervous system impacting the metabolic
and inﬂammatory potential of adipose tissue. Although the
effects of adiponectin on sympathetic nervous system control
have not been studied, clearly the reduction of inﬂammation,
the inhibition of free fatty acid release and the attendant
oxidative⁄nitrosative stress may be potential targets for future
therapeutic endeavours.
Growing evidence suggests that enhanced oxidative⁄
nitrosative stress and, in particular, increased production of the
potent oxidant peroxynitrite (a product of superoxide anion
radicals with nitric oxide) is a characteristic feature of both
experimental and clinical diabetes mellitus [40]. Peroxynitrite
causes damage to a variety of tissues by diverse effects, which
include: nitration and nitrosylation of protein; damage to DNA;
alteredgeneexpressionandchangesintranscriptionalregulation
and signal transduction; altered mitochondrial function; and
induction of microvascular endothelium necrosis in a variety of
tissues [40] [41] [42], including peripheral nerve, spinal cord,
dorsal root ganglion neurons and vasa nervorum of several
different models of both Type 1 and Type 2 diabetes [43].
Several markers of oxidative stress in plasma, including
superoxide and peroxynitrite, are elevated in patients with
diabetes with cardiac autonomic neuropathy [44].
These ﬁndings suggest the presence of peroxynitrite
cytotoxicity at both early and advanced stages of Type 1 and
Type 2 diabetes and, furthermore, at the pre-diabetic stage.
Enhanced nitrosative stress has also been documented in the
circulation [45] and cutaneous microvasculature of human
subjects with diabetes mellitus [46]. Monocyte nitrosylated
protein expression is a new biomarker of metabolic control and
inﬂammationinindividualswithdiabeteswithmacroangiopathy
and correlates with measuresof inﬂammation such as C-reactive
protein [47]. Moreover, cyclo-oxygenase-2 activation appears
to play an important role in the development of cardiac
autonomic neuropathy, as cyclooxygenase-2 gene inactivation
is protective against indexes of cardiac autonomic neuropathy,
oxidative stress and inﬂammation and prevents left ventricular
dysfunction and myocardial ﬁbrosis in experimental diabetes
[48].
A more detailed assessment of diabetic microvascular
complications and autonomic function is needed to determine
if this variable can be employed as a biomarker of the presence,
severity and progression of diabetic autonomic neuropathy and
accounts in part for the relatively low risk conferred by
hyperglycaemia alone (Diabetes Control and Complications
Trial and Epidemiology of Diabetes Interventions and
Complications study) and the greater risk reduction for
autonomic neuropathy with multiple risk factor reduction [14].
Conditions of autonomic imbalance associated with
cardiovascular risk
Metabolic syndrome
In a study of healthy individuals, prolonged mild hyper-
insulinaemia was shown to disrupt the circadian rhythm of
cardiac autonomic activity. Thus, the authors suggested that
early changes in the neural control of cardiac activity may
provide a potential mechanism mediating a pathophysiological
link between impaired glucose tolerance and cardiovascular
disease [49].
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the function of the autonomic nervous system as increased
activity of the sympathetic nervous system is associated with
several of the speciﬁc metabolic syndrome components (e.g.
obesity, hypertension, insulin resistance) [50] [51]. Unresolved,
however, is whether the aberrations of the autonomic nervous
systemcontributetothedevelopmentofthemetabolicsyndrome
or are a consequence of the metabolic syndrome. A recent study
of 1298 individuals with different numbers of metabolic
abnormalities showed that altered cardiac autonomic function
existed in individuals with one or two metabolic abnormalities.
Furthermore, as a result of cardiac autonomic dysfunction, but
notinsulinresistanceinpersonswithonemetabolicabnormality,
the authors suggested that altered cardiac autonomic function
precedes the presence of insulin resistance in the metabolic
syndrome [52]. Prospective studies are, however, needed to
answer this question with regard to the natural history. One
prospectivestudyof433non-obese,normotensivemenfollowed
for 5 years showed that autonomic dysfunction contributed to
the development of obesity as sympathetic overactivity (i.e.
plasma norepinephrine concentrations) and serum uric acid
levels predicted future weight gain and elevation of blood
pressure [53].
In individuals with a history of diabetes, it is well known that
dysfunction of the autonomic nervous system is a potential
complication. Impaired autonomic function may, however, be a
mechanism associated with early glucose dysmetabolism and
thus autonomic dysfunction may be involved in the pathogenic
pathway leading to the development of diabetes [54].
Sleep apnoea
In obstructive sleep apnoea there is repetitive collapse of the
upper airway during sleep. This leads to hypopnoea or apnoea
with corresponding oxygen desaturation. The pathophysiology
of obstructive sleep apnoea is multifactorial. Anatomical
contributions of the upper airway (e.g. fat deposits altering
pharyngeal size), as well as impaired peripheral⁄central control
of muscles via alterations to the autonomic nerve ﬁbres
involved in the upper airway reﬂexes, may contribute to the
pathogenesis [55]. There are signiﬁcant changes in sympathetic⁄
parasympathetic balance during the different stages of sleep
(Table 1) [56]. Note the increase in low frequency and low-
frequency⁄high-frequencyratioinrapideyemovementsleepand
thedecreaseinhighfrequency(Table 1).Clearly,disturbancesin
sleep architecture, such as obstructive sleep apnoea or even
changing duration of sleep can contribute signiﬁcantly to a
greater derangement in this balance, with large consequences on
metabolic function.
The prevalence of obstructive sleep apnoea in the diabetic
population varies from 17% in one study of men with Type 2
diabetes [57] to 30% in non-obese subjects with diabetes who
had diabetic autonomic neuropathy [58]. Differences in
prevalence rates vary as a result of methodology issues,
including different patient cohorts and different criteria used to
deﬁne the severity of the hypopnoea or apnoea events.
Individualswithobstructivesleepapnoeahaveincreasedlevels
of sympathetic activity [59] [60], resulting in autonomic nervous
system imbalance, potentially predisposing them to the
development of cardiac arrhythmias [61]. Thus, obstructive
sleep apnoea appears to be associated with adverse
cardiovascular outcomes [62]. In one study, the risk of sudden
death from cardiac causes for patients with obstructive sleep
apnoea during the sleep hours of 00.00 to 06.00 h was shown to
be 2.57 [63]. Obstructive sleep apnoea is associated with altered
glucose metabolism and inﬂammation [64]. Abnormal sleep
times [short (< 6 h) or long (> 8 h)] are related to increased risk
of Type 2 diabetes [65]. Although the potential mechanisms for
the increased risk of sudden death are many, obstructive sleep
apnoea in patients with diabetes complicated by autonomic
imbalancerepresentsincreasedriskforcardiovascularmorbidity
and mortality [55]. Treatment of obstructive sleep apnoea with
continuous positive airway pressure therapy has been shown to
improve vagal tone [66]. Four weeks of continuous positive
airway pressure reduced mean 24-h heart rate in men with
moderate-to-severeobstructivesleepapnoea,possiblybecauseof
reduced sympathetic activation [67]. Whether continuous
positive airway pressure may improve cardiac autonomic
neuropathy or reduce cardiac arrhythmias in association with
obstructive sleep apnoea in patients with diabetes requires
further study.
Impact of hypoglycaemia on autonomic function
Prior hypoglycaemic episodes attenuate the response of the
autonomic nervous system to subsequent hypoglycaemia [68]
andtospeciﬁccardiovascularstresses[69].Giventhatantecedent
hypoglycaemia also attenuates cardiovascular autonomic
control, it could have implications with regard to the use of
rigorous glycaemic control in individuals with diabetes.
Adler et al. [69] suggested that the impact of antecedent
hypoglycaemia on cardiovascular autonomic function could be
a potential explanation for the increase in cardiovascular
mortality reported in the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) study [70]. However, no
association between antecedent hypoglycaemia and increased
mortality in the ACCORD trial was shown, although cardiac
autonomic neuropathy clearly predicted events [71].
Table 1 Autonomic functions in different sleep stages
HRV Wakefulness Stage 2 REM Signiﬁcance
TF 6.5  6.2 6.3  5.8 11.2  10.2 0.001
LF 2.0  2.8 2.1  2.6 2.7  3.0 0.013
HF 1.2  1.5 1.7  2.4 1.3  2.7 0.012
LF⁄HF 2.7  2.6 2.0  2.2 3.9  3.6 0.001
HF, high frequency; HRV, heart rate variable; LF, low
frequency; REM, rapid eye movement; TF, total frequency.
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autonomic imbalance
The traditional view of cardiac autonomic neuropathy is that
there is an early phase of loss of parasympathetic function with
increased resting heart rate and abnormalities in the
expiration:inspiration ratio of heart rate variability. There may,
however,benoparasympatheticdenervationassuch,butsimply
early augmentation of sympathetic tone. Early in the natural
history of diabetes there is impairment of parasympathetic
function,witharelativeincreaseofsympatheticfunctioncausing
an imbalance of the sympathetic⁄parasympathetic tone. Later,
sympathetic denervation follows, beginning at the apex of the
ventricles and progressing towards the base of the heart [1],
leading to yet another imbalance, with an increase in propensity
to dysrhythmias.
Analysis of heart rate variability coupled with analysis of
respiratory activity provides a non-invasive and objective
method for assessing cardiac autonomic neuropathy and may
bederivedfromelectrocardiographrecordings[1].Incorporating
respiratory signalanalysis enables one to independently measure
each branch of the autonomic nervous system. Spectral analysis
of heart rate variability is an important tool to evaluate cardiac
autonomic neuropathy [1] . It decomposes a series of sequential
R-Rintervalsintoasetofsinusoidalwaves.Thepowerspectrum
is displayed with the magnitude of variability as a function
of frequency. The main frequency components are: very-
low-frequency components (< 0.04 Hz) related to ﬂuctuations
in vasomotor tone associated with thermoregulation, the low-
frequency component (0.04–0.15 Hz) associated with the
baroreceptor reﬂex and the high-frequency components
(0.15–0.4 Hz) related to respiratory activity [1]. The
cardiogram (from the electrocardiograph) only provides one
number (heart rate variability) for a two-part system (i.e.
parasympathetic and sympathetic). If the one number (heart rate
variability) changes, one cannot tell which part (parasympathetic
or sympathetic) changed. Respiratory analysis adds the second
number, identifying the parasympathetic activity that generates
respiratory sinus arrhythmia, thereby enabling respiratory sinus
arrhythmia to be analysed separately to identify parasympathetic
activity (i.e. respiration frequency area) (Fig.1 ) . H e a r t r a t e
variability which is mixed (parasympathetic and sympathetic)
can now be separated (i.e. respiration frequency area and low
frequency area) (Fig. 1).
Future directions in restoration of
autonomic balance and the impact on
morbidity and mortality
Lifestyle changes to restore balance
IntheDiabetesPreventionProgram,therapeuticlifestylechanges
which included appropriate diet and exercise induced a 25%
reduction in risk of autonomic dysfunction [72].
Endurance training improves heart rate variability in patients
with minimal abnormalities. However, one cannot use the
normal calculations for heart rate of 220 minus age to calculate
the maximum intensity and to derive a target for intensity of
exercise, because of the resting tachycardia in patients with
autonomic dysfunction. Therefore, individuals must rely on use
of perceived exertion to prescribe exercise intensity in diabetic
autonomic neuropathy [73]. Chronic exercise is associated with
enhanced cutaneous blood ﬂow in Type 2 diabetes [74],
restoration of baroreceptor sensitivity [75], as well as improved
vagal activity and exercise capacity after 12 weeks of endurance
training in early cardiac autonomic neuropathy, but not severe
cardiac autonomic neuropathy [76]. These results emphasize the
needforearlyaggressiveinterventionatthestageofphysiological
deﬁcits in nerve function. Perhaps the most enlightening
study was that of Motooka et al. [77], who showed that older
people walking their pet animal improved sympathetic⁄
parasympathetic balance, whereas the same exercise without
the animal was quite stressful, increasing the prevalence of low
frequencyamplitudes,indicatinglossofbalanceandsympathetic
activation.
Medications to restore sympathovagal balance
Disturbancesinautonomicbalance canarisefroman increase or
decreaseineithersympatheticorparasympathetictone.Eachcan
be restored to normal using appropriate medications (Fig.2 ) .
The use ofa-lipoic acid [78],a powerfulantioxidant,hasbeen
shown to improve heart rate variability. The role for reactive
oxygen species in diabetes-associated nerve blood ﬂow and
conduction deﬁcits was demonstrated in studies with the
‘universal’ antioxidant DL-a-lipoic acid, which combines free
radical and metal chelating properties with an ability (after
conversion to dehydrolipoic acid) to regenerate levels of other
antioxidants. Pharmacological tools targeting peroxynitrite
formation or promoting its decomposition have recently
been examined for their effects on autonomic neuropathy.
Several peroxynitrite decomposition catalysts have been
employed for preclinical studies of early peripheral diabetic
neuropathy and autonomic neuropathy. The peroxynitrite
decomposition catalysts Fe(III)tetrakis-2-(N-triethylene glycol
monomethyl ether)-pyridyl porphyrin (FP15) and Fe(III)
FIGURE 1 Parasympathetic and sympathetic measurement model. FRF,
fundamentalrespiratoryfrequency;HR,heartrate;Lfa,lowfrequencyarea;
Lfa⁄Rfa, sympathovagal balance; mHR, mean heart rate; RA, respiratory
activity;Rfa,respirationfrequencyarea;RSA,respiratorysinusarrhythmia.
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function in streptozotocin-diabetic rats and streptozotocin-
diabetic and ob⁄ob mice. The beneﬁcial effects of the protein
nitration inhibitor epicatechin have also been reported.
Multiple risk factor reduction has been shown to lower the
hazard ratio for autonomic neuropathy by 63% [14]. What the
importantelementswereintheStenoType 2studyhaveyettobe
determined. Even the maldistribution of cardiac sympathetic
innervation can be restored with excellent diabetes control [1]
[79].
An increase in heart rate variability has also been described
with the use of aldose reductase inhibitors, C-peptide, ACE
inhibitors(quinapril,ramipril,perindopril),angiotensinreceptor
blockers (losartan, telmisartan), cardioselective b-blockers
without intrinsic sympathomimetic activity (e.g. metoprolol),
digoxin and verapamil[1]. Autonomic imbalance and high post-
infarction morbidity and mortality are frequently observed in
patients with diabetes. Because the reduction in both recurrent
myocardial infarction and mortality in post-infarction patients
treated with b-blockers without intrinsic sympathomimetic
activity was higher in subjects with diabetes than subjects
without diabetes, it has been suggested that this high-risk group
could particularly beneﬁt from these agents.
To date, no results are available for advanced glycation end-
product inhibitors (AGEIs), statins, carnitine, peroxisome
proliferator activated receptors (PPARs), protein kinase C-b
inhibitors and anti-inﬂammatory agents and the effect on heart
rate variability. These agents are therefore some of the suggested
targets for future attention.
A paradigm of pharmaceutical approaches to reducing
inﬂammation and oxidative⁄nitrosative stress is illustrated in
Fig. 3 modiﬁed from that previously published [46].
Summary
Autonomic imbalance between the sympathetic and para-
sympathetic nervous system’s regulation of cardiovascular
function contributes to signiﬁcant morbidity and mortality for
individuals with diabetes. Obesity and the overproduction of
inﬂammatory cytokines have been implicated in the induction of
numerous pathogenic mechanisms that can be responsible for
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648 Diabetic Medicine ª 2011 Diabetes UKautonomic imbalance impacting deleterious processes that
increase and perpetuate cardiovascular risk. In addition,
hyperleptinaemia and a deﬁciency of adiponectin favour
sympathetic overactivity and the inﬂammatory cascade is
enhanced in the presence of sleep apnoea, a frequent partner in
diabetes and the metabolic syndrome. Restoration of autonomic
balance is possible and has been shown with therapeutic lifestyle
changes, increased physical activity, b-adrenergic blockers,
aldose reductase inhibitors, ACE inhibitors, angiotensin
receptor blockers, potent antioxidants such as a-lipoic acid,
andinanimalmodelsusinginhibitorsofperoxynitriteformation
and its decomposition. There are exciting new prospects for
pathogenesis-oriented intervention.
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